Your browser doesn't support javascript.
loading
Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
Sagara, Hironori; D'Andrea, Peter; Tanase, Ana-Maria; Pethe, Abhijit; Tanaka, Yukina; Matsuo, Kazutaka; Hosoe, Motoi; Nakamura, Yoichi.
Afiliação
  • Sagara H; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University, School of Medicine, Tokyo, Japan.
  • D'Andrea P; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Tanase AM; Novartis Pharma AG, Basel, Switzerland.
  • Pethe A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Tanaka Y; Novartis Pharma K.K, Tokyo, Japan.
  • Matsuo K; Novartis Pharma K.K, Tokyo, Japan.
  • Hosoe M; Novartis Pharma AG, Basel, Switzerland.
  • Nakamura Y; Department of Allergology, Medical Center for Allergy and Immune Diseases, Yokohama City Minato Red Cross Hospital, Kanagawa, Japan.
J Asthma ; 60(2): 403-411, 2023 02.
Article em En | MEDLINE | ID: mdl-35348408
ABSTRACT

INTRODUCTION:

The 52-week long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate (IND/GLY/MF) high-dose (150/50/160 µg) and IND/MF high-dose (150/320 µg) was evaluated in two studies enrolling Japanese patients with inadequately controlled asthma.

METHODS:

Study 1 (IND/GLY/MF) and Study 2 (IND/MF) were 52-week, phase III, open-label, single-arm, multicenter studies conducted in Japanese adult patients with inadequately controlled asthma. The primary endpoint was incidence and severity of treatment-emergent adverse events (AEs) over 52-weeks.

RESULTS:

In Study 1, 94 patients received IND/GLY/MF high-dose and 84 (89.4%) patients completed the 52-week study treatment; in Study 2, 51 patients received IND/MF high-dose and 48 (94.1%) patients completed the 52-week study treatment. In Study 1, 68.1% and 6.4% of 94 patients reported ≥1 AE and ≥1 serious AE (SAE) respectively. In Study 2, 78.4% of 51 patients reported ≥1 AE; no patients reported SAEs. The most commonly reported AEs were asthma (exacerbation; 30.9% and 54.9%) and nasopharyngitis (18.1% and 29.4%) in Study 1 and Study 2, respectively. Severe AEs including asthma (exacerbation) were reported in 13.8% and 13.7% of patients in Study 1 and Study 2, respectively. In Study 1, 10 patients (10.6%) reported treatment-related AEs, of which dysphonia (9 patients [9.6%]) was the most commonly reported; no treatment-related AEs were reported in Study 2. In Study 1, one death (not study drug-related) was reported after study discontinuation (92 days after last dose of study medication).

CONCLUSIONS:

Once-daily IND/GLY/MF and IND/MF high-dose were well-tolerated in Japanese patients with inadequately controlled asthma. No unexpected safety findings were observed.Supplemental data for this article is available online at.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Asma / Furoato de Mometasona / Acetatos Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Revista: J Asthma Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Asma / Furoato de Mometasona / Acetatos Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Revista: J Asthma Ano de publicação: 2023 Tipo de documento: Article